{"schema_version":"1.0","type":"article","title":"After Xtandi: Can Astellas Build an Oncology Platform?","url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.md","lang":"en","date":"2026-07-30","publish_at":"2026-07-30T08:00:00+08:00","updated_at":"2026-07-30","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["Astellas","Xtandi","Padcev","Vyloy","oncology","drug development"],"summary":"Xtandi still dominates Astellas oncology sales. The real test is whether Padcev, Vyloy and the next CLDN18.2 assets can become a repeatable post-LOE platform.","key_points":[],"facts":[],"sections":["Layer one: four products are on the market, but the portfolio remains concentrated","Layer two: product sales are not the same as the economics Astellas retains","Layer three: Padcev has entered a curative-intent setting; adoption is the next test","Layer four: Vyloy has first-mover advantage, but CLDN18.2 will not remain a one-player field","Layer five: Xospata provides a base, but it should not be overstated as a broad AML platform","Layer six: Astellas has prepared capital for life after Xtandi, but targets are not results","Four gates: when can the platform be considered proven?","Conclusion: Astellas is no longer “only Xtandi,” but it is too early to declare victory","Primary sources"],"references":[{"title":"[Astellas FY2025 Financial Results Presentation]","source":"","date":"","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_pre_en.pdf"},{"title":"[Astellas FY2025 Supplementary Materials]","source":"","date":"","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_sup_en.pdf"},{"title":"[Astellas/Pfizer: US approval of perioperative Padcev plus Keytruda in MIBC, July 13, 2026]","source":"","date":"","url":"https://newsroom.astellas.com/2026-07-13-us-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility"},{"title":"[FDA: 2025 perioperative approval of Padcev plus Keytruda in MIBC]","source":"","date":"","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer"},{"title":"[FDA: Vyloy approval and SPOTLIGHT/GLOW summary]","source":"","date":"","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma"},{"title":"[Astellas/Evopoint: XNW27011 licensing announcement]","source":"","date":"","url":"https://newsroom.astellas.com/2025-05-30-CLDN18-2-XNW27011"},{"title":"[ClinicalTrials.gov: phase 3 AZD0901 study in second-line or later gastric/GEJ cancer, NCT06346392]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06346392"},{"title":"[Innovent: phase 3 primary endpoint and China NDA acceptance for IBI343, June 4, 2026]","source":"","date":"","url":"https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=601"},{"title":"[FDA: Xospata approval]","source":"","date":"","url":"https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutation"},{"title":"[Astellas CSP2026 Presentation]","source":"","date":"","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/Investors-Meeting/astellas_csp2026_presentation_20260526_en.pdf"},{"title":"[Astellas 2026 JPM Healthcare Conference Script]","source":"","date":"","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/Investors-Meeting/44th_Annual_JPM_Healthcare_Conference_meeting_script_Astellas.pdf"},{"title":"[ScinoPharm Taiwan: commercial API portfolio]","source":"","date":"","url":"https://www.scinopharm.com/tw/products-detail/commercialAPI/"},{"title":"> This article is an analysis of public information for industry-research purposes. It is not medical advice, individual treatment advice or investment advice. Patient eligibility, benefits and risks should be determined from the applicable regulatory label and by qualified healthcare professionals.","source":"","date":"","url":""}],"images":[{"alt":"Astellas is no longer only Xtandi, but its oncology portfolio remains concentrated","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-01-en.svg"},{"alt":"Padcev moves from advanced disease into treatment before and after bladder-cancer surgery","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-02-en.svg"},{"alt":"Astellas has assembled the outline of a multi-tumor, multi-modality platform","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-03-en.svg"},{"alt":"Four validation gates for Astellas’ emerging oncology platform","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-04-en.svg"}],"cover_image":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/cover-en.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-30）。After Xtandi: Can Astellas Build an Oncology Platform?。https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-23-astellas-oncology-platform.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}